Friday, March 06, 2026

In Detail Full day, Friday, March 06, 2026, Timezone: America/Chicago

Hospitals urge regulators to halt drugmakers’ expanded 340B data policies

Emily Olsen / healthcaredive - The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.

AI Summary: Hospitals and provider groups are urging federal regulators to halt new drugmaker policies that expand claims-data reporting tied to 340B discounts, calling the requirements unlawful and administratively burdensome. The dispute pits safety-net providers against manufacturers seeking program transparency — a classic tug-of-war with patients’ financial stakes caught in the middle.

GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people

medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…

AI Summary: A large observational analysis suggests GLP‑1 receptor agonists — the headline-grabbing diabetes and weight-loss drugs — are linked to reduced risk of developing and dying from substance use disorders across multiple substances. Researchers urge cautious optimism: signals are intriguing, but causality remains unproven and more controlled trials are needed before rewriting addiction treatment playbooks.

AI blood test finds silent liver disease years before symptoms

sciencedaily - Researchers created an AI-driven liquid biopsy that scans patterns in fragments of DNA circulating in the blood. The system detected early liver fibrosis and cirrhosis—conditions that often go unnoticed until serious damage occurs. By analyzing genome-wid…

AI Summary: Researchers unveiled an AI‑driven liquid biopsy that scans genome‑wide cell‑free DNA fragment patterns to flag liver fibrosis, cirrhosis and chronic liver disease well before symptoms appear. Early results indicate the test can identify disease signals years ahead of clinical diagnosis, offering a shot at much earlier intervention — if practice and payers cooperate.